Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Prognostic Significance of Re-Induction Necessity Based on Day-14 Residual Disease and Age-Adjusted Consolidation Approaches in Acute Myeloid Leukemia

  • By

  • Abiola Bolarinwa

  • Muhammad Yousuf

  • Aref Al-Kali

  • Hassan B. Alkhateeb

  • Abhishek A. Mangaonkar

  • Antoine N. Saliba

  • Mehrdad Hefazi Torghabeh

  • Aasiya Matin

  • Michelle A. Elliott

  • Mark R. Litzow

  • William J. Hogan

  • Mithun V. Shah

  • Mrinal M. Patnaik

  • Animesh Pardanani

  • Dong Chen

  • Kaaren K. Reichard

  • Rong He

  • Naseema Gangat

  • Ayalew Tefferi

  • Kebede H. Begna

  • September 30, 2026

Share

Clinical Scorecard: Prognostic Significance of Re-Induction Necessity Based on Day-14 Residual Disease and Age-Adjusted Consolidation Approaches in Acute Myeloid Leukemia

At a Glance

CategoryDetail
ConditionAcute Myeloid Leukemia
Key MechanismsInduction treatment aims for complete remission; re-induction considered for residual disease on day 14.
Target PopulationPatients with acute myeloid leukemia undergoing intensive chemotherapy.
Care SettingOncology clinical practice

Key Highlights

  • Re-induction required for 27% of patients to achieve CR/CRi.
  • Median RFS was 18 months; OS was 76 months.
  • Age ≥65 years and ELN adverse karyotype were significant predictors of relapse and survival.
  • IDAC consolidation showed longer RFS and OS in older patients compared to anthracycline-based regimens.

Guideline-Based Recommendations

Diagnosis

  • Bone marrow assessment on day 14 recommended for residual disease.

Management

  • Consider re-induction for residual disease > 5% blasts.

Monitoring & Follow-up

  • Monitor for relapse-free survival and overall survival post-induction.

Risks

  • Age ≥65 years and adverse ELN karyotype increase risk of relapse and poor survival.

Patient & Prescribing Data

279 patients with AML diagnosed from 2004 to 2020.

Standard induction with '7 + 3' regimen; consolidation options include anthracycline-based or HiDAC/IDAC.

Clinical Best Practices

  • Utilize genetic risk stratification for treatment decisions post-CR/CRi.
  • Consider age and performance status when planning consolidation therapy.

Related Resources & Content

Original Source(s)

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

  • by Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A. Elliott, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Dong Chen, Kaaren K. Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H. Begna

  • September 30, 2026

Related Content

DNA Doesn’t Have to Die with Us

A pathologist's reflections on legacy, mutation, and protecting the integrity of the human genome

2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.

  • October 15, 2026

  • 1 min
Baptist Health Oncologist Rohan Garje Recognized for National Leadership in Cancer Treatment Guidelines

Clinical trials continue to inform how physicians treat advanced prostate cancer. The American Society of Clinical Oncology (ASCO) develops guidelines to help oncologists evaluate new evidence and apply it to clinical practice

  • by

  • October 9, 2026

  • 4 min